CNCR:NSD-Loncar Cancer Immunotherapy ETF (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 14.485

Change

-0.05 (-0.31)%

Market Cap

USD 0.01B

Volume

1.41K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The fund attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Inception Date: 13/10/2015

Primary Benchmark: Loncar Cancer Immunotherapy TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.79%

Management Expense Ratio: 0.79 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

N/A

USD 7.64B
PPH VanEck Pharmaceutical ETF 0.36 %

N/A

USD 0.73B
BBH VanEck Biotech ETF 0.35 %

N/A

USD 0.46B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

N/A

USD 0.20B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

N/A

USD 0.15B
GNOM Global X Genomics & Biotechnol.. 0.00 %

N/A

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

N/A

USD 0.02B

ETFs Containing CNCR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.54% 50% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.54% 50% F 66% D+
Trailing 12 Months  
Capital Gain 21.21% 75% C 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.21% 75% C 74% C
Trailing 5 Years  
Capital Gain -26.35% 13% F 35% F
Dividend Return 10.89% 88% B+ 43% F
Total Return -15.46% 22% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain -6.30% N/A N/A 30% F
Dividend Return -4.48% N/A N/A 31% F
Total Return 1.82% N/A N/A 43% F
Risk Return Profile  
Volatility (Standard Deviation) 31.63% N/A N/A 58% F
Risk Adjusted Return -14.16% N/A N/A 31% F
Market Capitalization 0.01B 11% F 14% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.